IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Immunoglobulin G deficiency subtypes in patients with asthma six months once a month intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on reducing the frequency of asthma exacerbations appreciate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

NCT07054034

Bronchial Asthma

ACTIVE_NOT_RECRUITING PHASE2

Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis

NCT00306033

Myasthenia Gravis

COMPLETED PHASE3

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

NCT00004682

Myasthenia Gravis

TERMINATED NA

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

NCT05659927

Asthma

ACTIVE_NOT_RECRUITING PHASE1

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915

Primary Immune Deficiency Disorders (PIDD)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients Registration

•It is required to ensure that the patients meet the inclusion criteria for this clinical trial, are free from any items of exclusion criteria, are explained about the participation in the clinical trial along with the informed consent forms.

Procedure

•six months once a month intravenous immunoglobulin (400mg/kg/4weeks)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immune Globulin

Immunoglobulin G Deficiency Associated with persistent asthma subtypes

Group Type EXPERIMENTAL

Immune Globulin

Intervention Type DRUG

6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immune Globulin

6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Immunoglobulin G Deficiency

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient from over 16 years to under 75 years
* Patients diagnosed with asthma over six months ago
* immunoglobulin G subtypes who were diagnosed with immune deficiency
* more than 2 years Upper and lower respiratory tract infections

, and asthma exacerbations in this regard.
* ① calculated creatinine clearance ≧ 50ml/min

* ALT and AST \<x 3 times the upper limit of normal

* ALP \<x 3 times the upper limit of normal

* total bilirubin \<x 1.5 times the upper limit of normal

Exclusion Criteria

* within six months of the onset of the experiment who received immunoglobulin therapy
* immune globulin for those with a history of hypersensitivity reactions
* six months ago, another clinical trial participants.
* Systemic steroids and immunomodulators, such as asthma control that may affect the resources required drug administration.
* pregnant or lactating women.

Minimum Eligible Age

16 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No